These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
304 related articles for article (PubMed ID: 17414226)
61. Lack of electrocardiographic effect of dexlansoprazole MR, a novel modified-release formulation of the proton pump inhibitor dexlansoprazole, in healthy participants. Vakily M; Wu J; Atkinson SN J Clin Pharmacol; 2009 Dec; 49(12):1447-55. PubMed ID: 19826060 [TBL] [Abstract][Full Text] [Related]
62. Pharmacokinetics and pharmacodynamics of three moxifloxacin dosage forms: implications for blinding in active-controlled cardiac repolarization studies. Mason JW; Florian JA; Garnett CE; Moon TE; Selness DS; Spaulding RR J Clin Pharmacol; 2010 Nov; 50(11):1249-59. PubMed ID: 20145260 [TBL] [Abstract][Full Text] [Related]
63. Improving the precision of QT measurements. Darpo B; Fossa AA; Couderc JP; Zhou M; Schreyer A; Ticktin M; Zapesochny A Cardiol J; 2011; 18(4):401-10. PubMed ID: 21769821 [TBL] [Abstract][Full Text] [Related]
64. Effects of the selective alpha 1a-adrenoceptor antagonist silodosin on ECGs of healthy men in a randomized, double-blind, placebo- and moxifloxacin-controlled study. Morganroth J; Lepor H; Hill LA; Volinn W; Hoel G Clin Pharmacol Ther; 2010 May; 87(5):609-13. PubMed ID: 20220748 [TBL] [Abstract][Full Text] [Related]
65. A Thorough QT Study to Evaluate the Effects of Supratherapeutic Doses of Ledipasvir on the QTc Interval in Healthy Subjects. German P; Mathias A; Brainard DM; Song Q; Ling J; Kearney BP Clin Pharmacol Drug Dev; 2018 Aug; 7(6):641-651. PubMed ID: 29058821 [TBL] [Abstract][Full Text] [Related]
66. Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes. Chatterjee DJ; Khutoryansky N; Zdravkovic M; Sprenger CR; Litwin JS J Clin Pharmacol; 2009 Nov; 49(11):1353-62. PubMed ID: 19737980 [TBL] [Abstract][Full Text] [Related]
67. Variability of heart rate correction methods for the QT interval. Desai M; Li L; Desta Z; Malik M; Flockhart D Br J Clin Pharmacol; 2003 Jun; 55(6):511-7. PubMed ID: 12814443 [TBL] [Abstract][Full Text] [Related]
68. Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study. Khindri S; Sabo R; Harris S; Woessner R; Jennings S; Drollmann AF BMC Pulm Med; 2011 May; 11():31. PubMed ID: 21615886 [TBL] [Abstract][Full Text] [Related]
69. Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trials. Harris SC; Morganroth J; Ripa SR; Thorn MD; Colucci S Postgrad Med; 2017 Jan; 129(1):69-80. PubMed ID: 27927048 [TBL] [Abstract][Full Text] [Related]
70. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression. Shelton RC; Prakash A; Mallinckrodt CH; Wohlreich MM; Raskin J; Robinson MJ; Detke MJ Int J Clin Pract; 2007 Aug; 61(8):1337-48. PubMed ID: 17627710 [TBL] [Abstract][Full Text] [Related]
71. Effect of Retosiban on Cardiac Repolarization in a Randomized, Placebo- and Positive-controlled, Crossover Thorough QT/QTc Study in Healthy Men and Women. Stier B; Fossler M; Liu F; Caltabiano S Clin Ther; 2015 Jul; 37(7):1541-54. PubMed ID: 26138866 [TBL] [Abstract][Full Text] [Related]
72. Statistical characteristics of moxifloxacin-induced QTc effect. Yan LK; Zhang J; Ng MJ; Dang Q J Biopharm Stat; 2010 May; 20(3):497-507. PubMed ID: 20358432 [TBL] [Abstract][Full Text] [Related]
73. Droperidol and ondansetron-induced QT interval prolongation: a clinical drug interaction study. Charbit B; Alvarez JC; Dasque E; Abe E; Démolis JL; Funck-Brentano C Anesthesiology; 2008 Aug; 109(2):206-12. PubMed ID: 18648229 [TBL] [Abstract][Full Text] [Related]
74. Thorough QT/QTc study in patients with advanced Parkinson's disease: cardiac safety of rotigotine. Malik M; Andreas JO; Hnatkova K; Hoeckendorff J; Cawello W; Middle M; Horstmann R; Braun M Clin Pharmacol Ther; 2008 Nov; 84(5):595-603. PubMed ID: 18650802 [TBL] [Abstract][Full Text] [Related]
75. Deferasirox does not induce QT/QTc-prolongation in healthy subjects. Sechaud R; Dumortier T; Balez S Int J Clin Pharmacol Ther; 2009 May; 47(5):321-7. PubMed ID: 19473594 [TBL] [Abstract][Full Text] [Related]
76. Effect of pomaglumetad methionil on the QT interval in subjects with schizophrenia. Zhang W; Mitchell MI; Knadler MP; Long A; Witcher J; Walling D; Annes W; Ayan-Oshodi M Int J Clin Pharmacol Ther; 2015 Jun; 53(6):462-70. PubMed ID: 25881753 [TBL] [Abstract][Full Text] [Related]
77. The use of beat-to-beat electrocardiogram analysis to distinguish QT/QTc interval changes caused by moxifloxacin from those caused by vardenafil. Fossa AA; Langdon G; Couderc JP; Zhou M; Darpo B; Wilson F; Wallis R; Davis JD Clin Pharmacol Ther; 2011 Sep; 90(3):449-54. PubMed ID: 21814193 [TBL] [Abstract][Full Text] [Related]
78. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Wedam EF; Bigelow GE; Johnson RE; Nuzzo PA; Haigney MC Arch Intern Med; 2007 Dec; 167(22):2469-75. PubMed ID: 18071169 [TBL] [Abstract][Full Text] [Related]
79. Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects. Darpö B; Sager P; MacConell L; Cirincione B; Mitchell M; Han J; Huang W; Malloy J; Schulteis C; Shen L; Porter L Br J Clin Pharmacol; 2013 Apr; 75(4):979-89. PubMed ID: 22882281 [TBL] [Abstract][Full Text] [Related]
80. Repeated supratherapeutic dosing of strontium ranelate over 15 days does not prolong QT(c) interval in healthy volunteers. Taubel J; Naseem A; Wang D; Arezina R; Lorch U; Camm AJ Br J Clin Pharmacol; 2012 Aug; 74(2):296-303. PubMed ID: 22283848 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]